BIO Comments on FDA Draft Guidance on Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Medication-Assisted Treatment
October 8, 2018
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Medication-Assisted Treatment.
The draft guidance is an important step in clarifying the FDA’s view of endpoints to demonstrate efficacy of therapies to treat opioid use disorder (OUD). It’s important to expand primary and secondary endpoints in clinical trials for medications to treat opioid use disorder, including the outcomes patients and clinicians said were important to them at the public meeting on patient-focused drug development for opioid use disorder.
BIO requests clarification on how the FDA defines relapse to illicit opioid use, and requests FDA consider other possible endpoints to demonstrate effectiveness of drugs. BIO recommends the FDA provide additional detail on Phase III studies for medication assisted treatments.
Download Full Comments Below
BIO Comment Letter Opioid Use Disorder Endpoints For Demonstrating Effectiveness Of Drugs For Medication-Assisted Treatment FDA-2018-D-2382
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
BIO submitted these comments in response to the United States Patent and Trademark Office’s May 10, 2024, Notice of Proposed Rulemaking regarding Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting.
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Medication-Assisted Treatment.
The draft guidance is an important step in clarifying the FDA’s view of endpoints to demonstrate efficacy of therapies to treat opioid use disorder (OUD). It’s important to expand primary and secondary endpoints in clinical trials for medications to treat opioid use disorder, including the outcomes patients and clinicians said were important to them at the public meeting on patient-focused drug development for opioid use disorder.
BIO requests clarification on how the FDA defines relapse to illicit opioid use, and requests FDA consider other possible endpoints to demonstrate effectiveness of drugs. BIO recommends the FDA provide additional detail on Phase III studies for medication assisted treatments.